RxDoctor Payments Data

Mohammed Qayyum, MD

Cardiovascular Disease · San Jose, CANPI 1679666994

Payments from drug & device makers

$132,262in general payments, 2019–2025

Across 443 payments — averaging $298.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Preventice Services, LLC$104K
  • Boston Scientific$9K
  • Acist Medical Systems, Inc.$3K
  • Abbott$3K
  • Biotronik Inc.$2K
  • Actelion Pharmaceuticals US, Inc.$2K
  • plus $9K from 31 others

What the payments were for

  • Consulting fees$113,00085%
  • Speaking & faculty fees$2,4502%
  • Travel & lodging$4310%
  • Food & beverage$16,09712%
  • Education$2840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$132,262 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,407,227
Medicare patients
407
Services billed
6,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban135$193,563
Repatha SureclickEvolocumab215$168,982
EliquisApixaban79$91,545
EntrestoSacubitril/Valsartan73$87,609
Praluent PenAlirocumab30$29,497
FarxigaDapagliflozin Propanediol23$26,612
Rosuvastatin Calcium408$7,508
Metoprolol Succinate317$4,465
Ezetimibe138$3,500
Carvedilol171$1,493
Flecainide Acetate39$1,478
SotalolSotalol Hcl56$1,467
Losartan Potassium165$1,414
Nebivolol Hcl15$1,367
Atorvastatin Calcium94$1,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$632$193,563135 claims
PfizerEliquis$350$91,54579 claims
NovartisEntresto$350$87,60973 claims
AstraZenecaFarxiga$351$26,61223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →